Traders Buy Large Volume of Gilead Sciences Put Options (GILD)
Shares of Gilead Sciences (NASDAQ:GILD) was the recipient of some unusual options trading activity on Thursday. Investors bought 25,601 put options on the company, StockRatingsNetwork reports. This represents an increase of approximately 215% compared to the typical volume of 8,138 put options.
In other Gilead Sciences news, EVP Norbert Bischofberger sold 90,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $62.54, for a total value of $5,628,600.00. Following the sale, the executive vice president now directly owns 2,159,643 shares in the company, valued at approximately $135,064,073. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on GILD. Analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday. Finally, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, September 25th. They now have a $66.00 price target on the stock. Six analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $67.57.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 67.36 on Friday. Gilead Sciences has a 1-year low of $32.07 and a 1-year high of $67.38. The stock has a 50-day moving average of $62.5 and a 200-day moving average of $56.5. The company has a market cap of $103.1 billion and a price-to-earnings ratio of 36.74.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 25th. The company reported $0.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the company posted $0.99 earnings per share. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $1.96 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.